Minutes
Drug Utilization Review Board Meeting
DATE: September 11, 2024

Meeting Purpose: Quarterly Drug Utilization Board Meeting
Meeting opened at 6:00 p.m. by Laura Spring, MD

The meeting was conducted under Massachusetts Public Meeting Law requirements.

Attendance: Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Sarah M McGee, MD; Laura Spring, MD; Rebekah Rice, RPh, CDCES; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

Absent:

Agenda Items:

- Welcome and Introductory Remarks
- Guest Speaker
- Minutes
- Pipeline Update
- Annual Special Populations Update
- RSV Quality Assurance Analysis and Seasonal Update
- Respiratory Agents, Inhaled Quality Assurance Analysis
- MHDL Update
- DUR Operational Update
- MassHealth Update
- Hypnotics Quality Assurance Analysis
- Open Forum

Agenda Item	Discussion	Conclusions/Follow Up
Guest Speakers	• Daniel Bassoff, Medical Knowledge Care Team at Sarepta Therapeutics, spoke on Elevidys.	**Follow Up** Informational/Advisory

Agenda Item	Discussion	Conclusions/Follow-up
Minutes	Motion to approve the minutes for June 2024 was made by Timothy Fensky, RPh and was seconded by Sarah M McGee, MD.	**Follow-up** Minutes are approved.

Agenda Item	Discussion	Conclusions/Follow-up
Pipeline Update	**Pipeline Update by Dr. Katelyn Meyer** This Pipeline Update provided a brief overview of clinical and regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.	**Follow-up** Informational/Advisory
Action	Discussion • Overview of Investigational Agents giroctocogene fitelparvovec and UX111 • Discussion of Potential Impact of the Agents Conclusions • If approved, giroctocogene fitelparvovec would become the second gene therapy approved for hemophilia A, joining Roctavian® (valcotogogene roxaparvovec). • If approved, UX111 would become the first and only FDA-approved therapy for Mucopolysaccharidosis (MPS) IIIA.	**Conclusion** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Annual Special Populations Update	**Annual Special Populations Update by Dr. Bhakti Patel and Dr. Kaelyn Boss** This overview was a summary of the current structure of the Drug Utilization Review Special Populations Program. It summarized clinical outcomes of the program over the past year.	**Follow-up** Informational/Advisory

Agenda Item	Discussion	Conclusions/Follow-up
Action	Discussion • Provided annual overview of the MassHealth Special Populations Program • Reviewed financial and clinical outcomes of pharmacist interventions • Outlined the Prior Authorization (PA) Recertification Outreach Program Conclusions/Recommendations • The Special Populations Program encourages collaboration among MassHealth programs to improve member outcomes. • Outcomes suggest that the MassHealth Special Populations Program has a positive clinical impact on MassHealth members and potential cost savings for MassHealth. • Plan to continue evaluation of the MassHealth Special Populations program to identify opportunities to expand services and evaluate outcomes.	**Conclusion** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Respiratory Syncytial Virus (RSV) Quality Assurance (QA) Analysis and Seasonal Update	**RSV Quality Assurance Analysis and Seasonal Update by Dr. Warren Smith** This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.	**Follow-up** Informational/Advisory
Action	Discussion • Reviewed the latest prophylactic options available for the prevention of RSV • Examined MassHealth utilization for the RSV prophylactic agents • Discussed American Academy of Pediatrics (AAP) and Advisory Committee on Immunization Practices (ACIP) recommendations • Provided an overview of the RSV pipeline Conclusions/Recommendations	**Conclusion** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up

	• There are now multiple agents to prevent RSV lower respiratory tract disease (LRTD) in infants (Beyfortus®, Synagis®, maternal immunization with Abrysvo®).
	• For the 2024-2025 RSV season, PA criteria for Synagis® will require a step-through of Beyfortus®; Beyfortus® will be available without PA for members <8 months and PA will be required for members between 8 and 19 months.
	• Abrysvo®, Arexvy®, and mResvia® are available for adults ≥60 years of age (one of which, Arexvy®, is approved for patients ≥50 years of age).
	  ○ PA will be required for members outside of the above patient populations.
	  ○ ACIP recommendations for RSV vaccines include vaccination for patients 60 to 74 years of age who are at increased risk and all patients ≥75 years of age.
	• The pipeline includes investigational agents, such as Clesrovimab, which have the potential to impact the RSV prophylactic landscape in infants even further.	

Agenda Item	Discussion	Conclusions/Follow-up
Inhaled Respiratory Agents	**<u>Inhaled Respiratory Agents by Dr. Karen Stevens</u>** This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.	**<u>Follow-up</u>** Informational/Advisory
Action	Discussion • Provided an overview of asthma and chronic obstructive pulmonary disease (COPD) treatment • Described current MassHealth management for inhaled respiratory agents • Presented current MassHealth utilization and PA summaries • Reviewed subanalyses of short-acting beta-agonist (SABA) utilization, product discontinuations, and pipeline • Discussed recommendations following QA analysis Conclusions/Recommendations • Effective November 12, 2024, remove PA from Asmanex® Twisthaler to allow access to additional inhaled corticosteroid (ICS) inhaler, given shortages of Asmanex® HFA.	**<u>Conclusion</u>** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
	• Symbicort® will be listed with PD designation effective November 12, 2024. • Future SABA analysis will include subgroups of interest (e.g., diagnosis, age, TPL, etc.).	

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Drug List (MHDL) Update	**<u>MHDL Update by Dr. Chris Nelson</u>** MHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout.	**<u>Follow-up</u>** Informational/Advisory

Action	Discussion
	• Effective October 1, 2024:
	  ○ There were 16 additions the MHDL Drug list.
	  ○ There were 17 changes in PA status.
	• There were several changes to Coverage Status for Medical Billing, Brand Name Preferred Over Generic List; 90-day Initiative; and Updates and Changes to the MHDL.
		<u>Conclusion</u>
		The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
DUR Operational Update	**<u>DUR Operational Update by Dr. Kristen Danis</u>** DUR operational overview included statistics associated with PA review and PA response, and call center metrics.	**<u>Follow-up</u>** Informational/Advisory
Action	Discussion • Operational statistics, including PA and call center metrics up to December 31, 2024, were discussed • All metrics met or exceeded service level agreements.	**<u>Conclusion</u>** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Update	**<u>MassHealth Update by Dr. Kimberly Lenz</u>** MassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.	**<u>Follow-up</u>** Informational/Advisory
Action	Discussion • Reviewed current clinical program initiatives • Provided direct negotiation status update • Discussed operational updates	**<u>Conclusion</u>** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Hypnotics Quality Assurance Analysis	**<u>Oncology Immunotherapy Quality Assurance Analysis by Dr. Amy Dionne</u>** This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.	**<u>Follow-up</u>** Informational/Advisory
Action	Discussion • This presentation was tabled until the next DUR Board meeting.	**<u>Conclusion</u>** The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Open Forum	**<u>Open Forum</u>**	**<u>Follow-up</u>** Informational/Advisory
Action	Discussion • This presentation was tabled until the next DUR Board meeting.	**<u>Conclusion</u>** N/A

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: _____